Consider the risk of potential drug interactions when co-prescribing triptans with other medications

Abstract

Triptans generally have a low potential for drug interactions, with pharmacodynamic interactions likely to be of greater clinical significance than pharmacokinetic interactions. The most notable pharmacodynamic interactions include additive vasoconstrictor effects (e.g. with concomitant ergots) and serotonin syndrome (e.g. with concomitant selective serotonin reuptake inhibitors).